Tag archive for: oncology

The start of the school year is often a time for reflection and renewal. It’s a period when many people think about their future prospects: the perfect opportunity to explore continuing education options! To mark the occasion, we’d like to introduce you to one of our 198 university diplomas (DU) and inter-university diplomas (DIU): the DU in “From Normal Cells to Tumor Cells.” To do so, we sat down with the two co-directors of this program, Ms. Szablewski and Mr. Ramirez. Interview.

 

Ms. Szablewski, Mr. Ramirez, good morning. Could you please briefly introduce yourselves?

VS: I am Dr. Vanessa Szablewski, a Medical Technologist (MCU-PH) in Pathological Anatomy and Cytology at Montpellier University Hospital. I specialize in hematopathology and ENT pathology. For my research, I am affiliated withINSERM UMR 1058, Pathogenesis and Control of Chronic and Emerging Infections. My research focuses on the role of Human Papillomaviruses (HPVs) in cancers of the head and neck region.

JMR: I have held a Ph.D. in Biological Sciences for Health since 2005. After completing my dissertation, I conducted several postdoctoral fellowships abroad: in Washington, D.C., in the United States; at the University Hospital of Geneva in Switzerland; and at the CIC (Centro de Investigación contra el Cáncer) in Spain, before finally returning to France to join the IRMB in Montpellier. In 2015, I was hired as an associate professor at the Montpellier-Nîmes Faculty of Medicine in Professor Thierry Lavabre-Bertrand’s department, where I teach histology and cell biology. In 2019, Vanessa and I created the first website featuring virtual slides combining three disciplines: anatomy, pathological anatomy, and histology.

 

You are both directors of the university diploma program “From Normal Cells to Tumor Cells.” What motivated you to create this program?

JMR: Histology and pathological anatomy are two closely related disciplines; it struck me as essential for a researcher in the health field to have a solid understanding of histology (the study of tissues) as well as pathological tissues.

 

Who is this training primarily intended for? How long does it last?

VS: This program is designed for all researchers working in the field of oncology, as well as those interested in learning about human tissues and the diseases associated with them. It is also intended for physicians seeking to pursue a career in research or for oncologists wishing to acquire a solid foundation in scientific oncology. The program spans one academic year, but classes are held between February and June. The curriculum includes 52 hours of instruction, divided into 6 modules.

 

What added value will future graduates gain from this program? Does it open up new career paths for enrolled students?

JMR: The primary benefits include the acquisition of new core skills that will better equip future physicians and researchers in the field of oncology to perform their duties. Additionally, for all future physicians, this training will enable them to better interpret medical findings provided by a pathologist.

 

On Thursday, January 27, 2022, Dr. Catherine Alix-Panabières received the prestigious Savchuk Prize at the 15th Oncology Biennial for her work on “liquid biopsies.” A look back at 23 years of research in the field of oncology.

A career focused on the development of liquid biopsy

Dr. Alix-Panabières, director of the Rare Human Circulating Cells (CCRH) laboratory at Montpellier University Hospital, has been dedicated to her research for 23 years. Coined by her in 2010 with her German collaborator, Professor Klaus Pantel of Hamburg, the term “liquid biopsy”—which complements tissue biopsy—refers to a blood test that is performed repeatedly during a patient’s treatment.

 

A non-invasive procedure

A liquid biopsy provides access to circulating cells or particles released by the primary tumor or metastases. The advantage? It allows for the repeated, non-invasive monitoring of tumors located in hard-to-reach areas. After the blood sample is collected, it provides information on the tumor’s progression and, consequently, the effectiveness of treatment.

His research focuses on three key areas:

  1. Understanding the biology of the tumor and its prognosis.
  2. Technology: Dr. Alix-Panabières is working on a patent for this new technique, which enables the detection of circulating tumor cells.
  3. A translational clinical study. Liquid biopsy allows treatment to be tailored to each patient’s stage of disease, particularly when initiating treatment.

We extend our heartfelt congratulations to Dr. Catherine Alix-Pananières on winning this award!